Koninklijke Philips Corporation N.v.

Dianne Arnoldina Margaretha Wilhelmina Van Strijp

Anne Godefrida Catharina Van Brussel

Ralf Hoffmann

Hendrik Jan Van Ooijen

Marcia Alves De Inda

Janneke Wrobel

Eveline Den Biezen-Timmermans

Anja Van De Stolpe

Joannes Baptist Adrianus Dionisius Van Zon

Robert Van Gog

Ralf Dieter Hoffmann

Jenneke Wrobel

Johannes Baptist Adrianus Dionisius Van Zon

Márcia Alves De Inda

Eveline Catharina Anna Clasina Den Biezen

Eveline Den Biezen - Timmermans

The present invention relates to methods for diagnosing, monitoring or prognosticating prostate cancer or the progression state of prostate cancer wherein said method determines the state of the prostate cancer, based on the expression level of phosphodiesterase 4D (PDE4D) variants. The invention further relates to a method of identifying an individual for eligibility for prostate cancer therapy. The invention also relates to products for the analysis of phosphodiesterase 4D (PDE4D) variants as well as pharmaceutical compositions modulating the activity and/or expression of PDE4D variants.

Methods of prostate cancer prognosis

A bioinformatics method for determining a risk score that indicates a risk that a subject, in particular a human, will experience a negative clinical event within a certain period of time. The risk score is based on a unique combination of activities of two or more cellular signaling pathways in a subject, wherein the selected cellular signaling pathways are the TGF-&#x3b2; pathway and one or more of a PI3K pathway, a Wnt pathway, an ER pathway, and an HH pathway. The invention includes an apparatus with a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. The bioinformatics invention allows for more accurate prognosis of specific negative clinical events in a patient with, for example, a tumor or cancer, such as disease progression, recurrence, development of metastasis, or even death.

Superior bioinformatics process for identifying at risk subject populations

Methods are described for stratifying patient risk for patients with prostate cancer and for providing a treatment recommendation to a patient based on a phosphodiesterase 4D variant 7 (PDE4D7) risk score. A diagnostic kit and a computer program product for the analysis and determination of the PDE4D7 risk score are also described.

Risk scores based on human phosphodiesterase 4D variant 7 expression

A bioinformatics process which provides an improved means to detect TGF-&#x3b2; cellular signaling pathway in a subject, such as a human, based on the expression levels of one or more unique target gene(s) of the TGF-&#x3b2; cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of TGF-&#x3b2; cellular signaling pathway target genes.

Determination of TGF-&#x3b2; pathway activity using unique combination of target genes

Growing community of inventors

Eindhoven, Netherlands

Dianne Arnoldina Margaretha Wilhelmina Van Strijp